Tags

Type your tag names separated by a space and hit enter

Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck.
Head Neck. 2006 Dec; 28(12):1090-8.HN

Abstract

BACKGROUND

Postopertative adjuvant chemoradiotherapy recently became an established modality for patients with selected high-risk locally advanced head and neck cancers. The optimal treatment of unknown primary squamous cell cancer of the head and neck (SCCHN) continues to be controversial, since major randomized studies excluded those patients.

METHODS

We conducted a retrospective review of patients treated during 1995 to 2002 for unknown primary SCCHN. All patients were treated with a neck dissection followed by concurrent high-dose cisplatin (100 mg/m(2)) and bilateral neck radiotherapy.

RESULTS

Thirty-seven patients were identified with nodal disease distribution of N1 (5%), N2a (22%), N2b (41%), N2c (8%), N3 (22%), and Nx (3%). Modified neck dissection was done on the majority (30/37 = 81%) of patients. With a median follow-up of 42 months among the survivors, very few patients had regional recurrence (5%) or distant failure (11%), and 89% of patients were alive. The actuarial 5-year overall survival rate could not be estimated because there were no deaths beyond 20 months after surgery. Substantial yet acceptable acute and late morbidities were demonstrated in this cohort of patients.

CONCLUSIONS

Postoperative chemoradiotherapy is of potential benefit to patients with unknown primary SCCHN by improving survival and reducing failures. This treatment warrants further prospective evaluation.

Authors+Show Affiliations

Division of Hematology/Oncology and Transplantation (HOT), Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16933316

Citation

Shehadeh, Nasfat J., et al. "Benefit of Postoperative Chemoradiotherapy for Patients With Unknown Primary Squamous Cell Carcinoma of the Head and Neck." Head & Neck, vol. 28, no. 12, 2006, pp. 1090-8.
Shehadeh NJ, Ensley JF, Kucuk O, et al. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. Head Neck. 2006;28(12):1090-8.
Shehadeh, N. J., Ensley, J. F., Kucuk, O., Black, C., Yoo, G. H., Jacobs, J., Lin, H. S., Heilbrun, L. K., Smith, D., & Kim, H. (2006). Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. Head & Neck, 28(12), 1090-8.
Shehadeh NJ, et al. Benefit of Postoperative Chemoradiotherapy for Patients With Unknown Primary Squamous Cell Carcinoma of the Head and Neck. Head Neck. 2006;28(12):1090-8. PubMed PMID: 16933316.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. AU - Shehadeh,Nasfat J, AU - Ensley,John F, AU - Kucuk,Omer, AU - Black,Carri, AU - Yoo,George H, AU - Jacobs,John, AU - Lin,Ho-Sheng, AU - Heilbrun,Lance K, AU - Smith,Daryn, AU - Kim,Harold, PY - 2006/8/26/pubmed PY - 2007/1/31/medline PY - 2006/8/26/entrez SP - 1090 EP - 8 JF - Head & neck JO - Head Neck VL - 28 IS - 12 N2 - BACKGROUND: Postopertative adjuvant chemoradiotherapy recently became an established modality for patients with selected high-risk locally advanced head and neck cancers. The optimal treatment of unknown primary squamous cell cancer of the head and neck (SCCHN) continues to be controversial, since major randomized studies excluded those patients. METHODS: We conducted a retrospective review of patients treated during 1995 to 2002 for unknown primary SCCHN. All patients were treated with a neck dissection followed by concurrent high-dose cisplatin (100 mg/m(2)) and bilateral neck radiotherapy. RESULTS: Thirty-seven patients were identified with nodal disease distribution of N1 (5%), N2a (22%), N2b (41%), N2c (8%), N3 (22%), and Nx (3%). Modified neck dissection was done on the majority (30/37 = 81%) of patients. With a median follow-up of 42 months among the survivors, very few patients had regional recurrence (5%) or distant failure (11%), and 89% of patients were alive. The actuarial 5-year overall survival rate could not be estimated because there were no deaths beyond 20 months after surgery. Substantial yet acceptable acute and late morbidities were demonstrated in this cohort of patients. CONCLUSIONS: Postoperative chemoradiotherapy is of potential benefit to patients with unknown primary SCCHN by improving survival and reducing failures. This treatment warrants further prospective evaluation. SN - 1043-3074 UR - https://www.unboundmedicine.com/medline/citation/16933316/Benefit_of_postoperative_chemoradiotherapy_for_patients_with_unknown_primary_squamous_cell_carcinoma_of_the_head_and_neck_ L2 - https://doi.org/10.1002/hed.20470 DB - PRIME DP - Unbound Medicine ER -